Safety and Efficacy of the Vascular Closure Device (Tonbridge) in Hemostasis Treatment of Femoral Artery Puncture

Exclusion Criteria

• •Ipsilateral common femoral artery occlusion or lumen diameter \< 5mm;
• •Inability to walk;
• •Allergy to contrast media;
• •Allergy to PGA or PEG; subjects with a history of common femoral artery surgery, percutaneous transluminal angioplasty (PTA), stent implantation, or vascular graft;
• •Subjects with bleeding tendency, such as thrombocytopenia (platelet count \<100×109/L), hemophilia, von willebrand diseases, pre-procedure INR \>1.5, etc.;
• •Subjects have taken anticoagulants for a long term before the procedure and have blood coagulation disorders;
• •BMI \>40kg/m\^2;
• •Subjects receive thrombolytic therapy (such as streptokinase, urokinase, t-PA) within≤24 hours before vascular closure;
• •Local infections or skin infections of the investigational limb;
• •Subjects with target femoral artery dissection or aneurysm within 30 days before intervention procedure;
• •Subjects with puncture site have been punctured through the posterior wall of the femoral artery, or have been punctured several times (≥3 times), or have bleeding or hematoma on the femoral artery puncture site during the procedure;
• •Subjects with clinically significant peripheral vascular diseases (such as severe calcification, arteritis, stenosis, etc) near the puncture site;
• •Women who are pregnant or breastfeeding, OR men or women who plan to have a child in the next 6 months;
• •Subjects who are enrolled in other clinical trials and don't complete;
• •Subjects are considered not suitable for enrollment by the investigators.